GLP1R and obesity disorder: The glucagonlike peptide-1 (GLP-1) receptor agonist (RA), the experimental drug orforglipron (non-peptide) was pivoted by the researcher (Funded by Eli Lilly; GZGI ClinicalTrials.gov number, NCT05051579) as a once-daily oral therapy for weight reduction in adults with obesity.